Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

1.3K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.3K
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

981
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
981
CNS Depressants: Alcohol and Nicotine01:27

CNS Depressants: Alcohol and Nicotine

1.7K
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
1.7K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

379
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
379
Anxiolytic Drugs: Benzodiazepines and Buspirone01:29

Anxiolytic Drugs: Benzodiazepines and Buspirone

3.1K
Benzodiazepines are a class of anxiolytic drugs known for their rapid efficacy and high therapeutic-to-lethal dose ratio, but with a potential risk of drug dependence. These drugs are lipophilic, allowing for rapid absorption after oral administration, eventually reaching the central nervous system (CNS). Once in the CNS, benzodiazepines bind to the allosteric site of the GABAA receptor. This binding enhances the inhibitory effects of the neurotransmitter GABA. By doing so, they prevent...
3.1K
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

2.3K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
2.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Serotonergic Polypharmacology of 2-Halogenated Tryptamines.

bioRxiv : the preprint server for biology·2026
Same author

Can Psychiatric Genetics Advance Without Incorporating a Life Course Perspective?

Biological psychiatry·2026
Same author

An Open-Source Restraint System for Magnetic Resonance Imaging in Awake Rats.

eNeuro·2026
Same author

Investigating the polygenic relationship between heavy cannabis use and schizophrenia in the All of Us Research Program.

Psychological medicine·2025
Same author

FARESHARE: An open-source apparatus for assessing drinking microstructure in socially housed rats.

NPP - digital psychiatry and neuroscience·2025
Same author

Effects of prenatal cannabis exposure on offspring mental health: A focus on the role of the immune system.

Neuroscience and biobehavioral reviews·2025

Related Experiment Video

Updated: Apr 29, 2026

Self-Administration of Drugs in Mouse Models of Feeding and Obesity
03:37

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Published on: June 8, 2021

4.3K

Desipramine enhances the ability of risperidone to decrease alcohol intake in the Syrian golden hamster.

Danielle Gulick1, David T Chau1, Jibran Y Khokhar1

  • 1Department of Psychiatry, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.

Psychiatry Research
|May 20, 2014
PubMed
Summary
This summary is machine-generated.

Combining risperidone with desipramine, a norepinephrine reuptake inhibitor, may reduce alcohol drinking in hamsters. This suggests potential new treatments for alcoholism and schizophrenia.

Keywords:
AddictionAlcoholismAntipsychoticNorepinephrineNorepinephrine reuptake inhibitorSchizophrenia

More Related Videos

Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

1.7K
Measuring In Vivo Changes in Extracellular Neurotransmitters During Naturally Rewarding Behaviors in Female Syrian Hamsters
10:23

Measuring In Vivo Changes in Extracellular Neurotransmitters During Naturally Rewarding Behaviors in Female Syrian Hamsters

Published on: September 12, 2017

9.6K

Related Experiment Videos

Last Updated: Apr 29, 2026

Self-Administration of Drugs in Mouse Models of Feeding and Obesity
03:37

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Published on: June 8, 2021

4.3K
Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

1.7K
Measuring In Vivo Changes in Extracellular Neurotransmitters During Naturally Rewarding Behaviors in Female Syrian Hamsters
10:23

Measuring In Vivo Changes in Extracellular Neurotransmitters During Naturally Rewarding Behaviors in Female Syrian Hamsters

Published on: September 12, 2017

9.6K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Psychiatry

Background:

  • Clozapine, an atypical antipsychotic, reduces alcohol drinking, potentially via dopamine D2 and norepinephrine α-2 receptor interactions.
  • Risperidone, another atypical antipsychotic, does not decrease alcohol drinking despite potent blockade of these receptors.

Purpose of the Study:

  • To investigate if combining risperidone with desipramine enhances alcohol drinking reduction in Syrian golden hamsters.
  • To explore the role of norepinephrine reuptake inhibition in modulating risperidone's effect on alcohol consumption.

Main Methods:

  • Syrian golden hamsters were given access to alcohol (15% v/v) until a stable drinking baseline was established.
  • Animals were administered daily treatments of risperidone, desipramine, or a combination for 20 days.

Main Results:

  • Risperidone alone (0.2mg/kg) produced only a transient decrease in alcohol intake.
  • Combining risperidone (0.2mg/kg) with desipramine (1.0mg/kg or 5.0mg/kg) resulted in a more substantial and sustained reduction in alcohol drinking compared to risperidone alone.

Conclusions:

  • Norepinephrine reuptake inhibition may enhance the efficacy of risperidone in reducing alcohol consumption.
  • Findings suggest potential therapeutic strategies for treating alcoholism, particularly in patients with schizophrenia.